RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:146

Differentiated thyroid carcinoma

low confidenceDisorder

Also known as: Papillary or follicular thyroid carcinoma · Well-differentiated thyroid carcinoma

Publications

19,713

Trials

132

Interventional, condition-specific

Researchers

1,259

Distinct authors in sample

Gene link

—

Readiness

5/6

Stages with a signal

Clinical definition (Orphanet)

A rare, slow-growing, epithelial thyroid carcinoma typically presenting as an asymptomatic thyroid mass and is classed as either papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) or Hurthle cell thyroid cancer (HCTC).

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (11)

differentiated thyroid cancer · differentiated thyroid carcinoma · differentiated thyroid gland cancer · differentiated thyroid gland carcinoma · papillary or follicular thyroid carcinoma · thyroid gland differentiated carcinoma · thyroid gland well differentiated carcinoma · well differentiated thyroid carcinoma · well differentiated thyroid gland carcinoma · well-differentiated thyroid cancer · well-differentiated thyroid carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

5/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    19,713 matched papers (12,317 in last 10 years) Source

  3. Phenotype characterisedPresent

    43 HPO annotations (e.g. Dysphagia; Lymphadenopathy; Dysphonia) Source

  4. Animal modelPresent

    17 genotype models (Mus musculus) Source

  5. Orphan designationPresent

    4 FDA designations (2 FDA orphan-indication approvals) — e.g. selumetinib Source

  6. Interventional trialPresent

    132 matched on ClinicalTrials.gov (35 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

43

Associated phenotypes · MONDO:0015447

  • Dysphagia
  • Lymphadenopathy
  • Dysphonia
  • Weight loss
  • Primary hyperparathyroidism

Showing 5 of 43 — open Monarch for the full list.

Animal models (Monarch / Alliance)

17

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

4

Designations · 2 with FDA orphan-indication approval

  • FDA selumetinibDifferentiated Thyroid Cancer · 2016-05-10 · Not FDA Approved for Orphan Indication
  • FDA TiratricolWell-Differentiated Thyroid Cancer · 1991-08-13 · Not FDA Approved for Orphan Indication
  • FDA pralsetinib (Gavreto)anaplastic thyroid cancer Thyroid cancer medullary papillary thyroid cancer Differentiated Thyroid Cancer · 2020-05-26
  • FDA selpercatinib (RETEVMO)anaplastic thyroid cancer Thyroid cancer medullary Thyroid Cancers Differentiated Thyroid Cancer · 2019-11-21

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

72

Drugs / clinical candidates · MONDO_0015447

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

19,713

19,713 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

19,713 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

12,317 in the last 10 years · low confidence

Phrase hits: 19,713 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,259

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang J7 papers · 2026

    Key Laboratory of Head and Neck Cancer Translation Research of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.

    Papers in Europe PMC
  2. 02
    Li J5 papers · 2026

    General Medicine Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan city, China.

    Papers in Europe PMC
  3. 03
    Li X5 papers · 2026

    Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No. 127, Changle West Road, Xi'an, 710000, Shaanxi, China.

    Papers in Europe PMC
  4. 04
    Li Y5 papers · 2026

    Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.

    Papers in Europe PMC
  5. 05
    Wang X5 papers · 2026

    Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.

    Papers in Europe PMC
  6. 06
    Zantut-Wittmann DE5 papers · 2026

    Endocrinology Division, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil. zantutw@unicamp.br.

    Papers in Europe PMC
  7. 07
    Liu X4 papers · 2026

    Department of Ultrasound, China-Japan Friendship Hospital, Beijing, China.

    Papers in Europe PMC
  8. 08
    Cabanillas ME3 papers · 2026

    Department of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, Texas.

    Papers in Europe PMC
  9. 09
    Elisei R3 papers · 2026

    Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

    Papers in Europe PMC
  10. 10
    Ferlito A3 papers · 2025

    Coordinator of the International Head and Neck Scientific Group, 35125 Padua, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

132

interventional trials for this specific condition

132 interventional trials matched this specific condition name; 35 currently recruiting in our sample.

Data as of 11 September 2026

132 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.8th percentile).

low confidence · 98.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

132 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

41 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 11 · after dedupe 10 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 10 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (10)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Differentiated thyroid carcinoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Differentiated thyroid carcinoma" OR "Papillary or follicular thyroid carcinoma" OR "Well-differentiated thyroid carcinoma" OR "differentiated thyroid cancer" OR "differentiated thyroid gland cancer" OR "differentiated thyroid gland carcinoma" OR "thyroid gland differentiated carcinoma" OR "thyroid gland well differentiated carcinoma" OR "well differentiated thyroid carcinoma" OR "well differentiated thyroid gland carcinoma" OR "well-differentiated thyroid cancer")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Differentiated thyroid carcinoma" OR "Papillary or follicular thyroid carcinoma" OR "Well-differentiated thyroid carcinoma" OR "differentiated thyroid cancer" OR "differentiated thyroid gland cancer" OR "differentiated thyroid gland carcinoma" OR "thyroid gland differentiated carcinoma" OR "thyroid gland well differentiated carcinoma" OR "well differentiated thyroid carcinoma" OR "well differentiated thyroid gland carcinoma" OR "well-differentiated thyroid cancer"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 132 interventional · 41 observational · 2 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (19713) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T12:38:57.192Z